Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer’s Disease
Key claim: A 700-person RCT will test whether the Brain Safe consumer app reduces older adults’ exposure to strong anticholinergic drugs linked to Alzheimer’s disease risk versus an attention-control medication-list app.
Abstract
This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.
Why this matters
Anticholinergic burden is one of the better-documented modifiable dementia-risk exposures, and Brain Safe is a rare case of a consumer app being tested at RCT scale rather than shipped on mechanism alone. The trend worth tracking is deprescribing moving into the direct-to-consumer app layer; the evidence question — whether a reminder app actually shifts prescriptions or outcomes — remains open pending readout.